News
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...
The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...
2hon MSN
Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke ...
Beyond the Scale” focuses on obesity as a chronic disease - urging empathy, early intervention, and evidence-based care.
Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback